Format

Send to

Choose Destination
Pathol Res Pract. 2015 Nov;211(11):883-91. doi: 10.1016/j.prp.2015.07.004. Epub 2015 Jul 17.

Successful treatment of both double minute of C-MYC and BCL-2 rearrangement containing large B-cell lymphoma with subsequent unfortunate development of therapy-related acute myeloid leukemia with t(3;3)(q26.2;q21).

Author information

1
Department of Pathology, University of California San Diego Health System, La Jolla, CA 92093-0960, United States.
2
Division of Hematology, Department of Medicine, University of California San Diego Health System, La Jolla, CA 92093-0960, United States.
3
Department of Pathology, University of California San Diego Health System, La Jolla, CA 92093-0960, United States. Electronic address: huw003@ucsd.edu.

Abstract

Double minute chromosomes (DMs), although relatively frequently encountered in solid tumors, are rare in hematologic neoplasms such as acute myeloid leukemia (AML), and even rarer in lymphoid neoplasms. t(3;3)(q26.2;q21) is a very rare genetic alteration observed in myeloid neoplasm. Herein we report an interesting and unique case of concomitant C-MYC DMs and t(14;18)-containing large B-cell lymphoma, which was successfully treated with R-hyper-CVAD; unfortunately, the patient has developed a therapy-related AML (t-AML) 2 years since the start of his lymphoma treatment. His t-AML contains both t(3;3)(q26.2;q21) and monosomy 7, and the patient died of AML 10 months after the initial diagnosis of t-AML despite clinical remission. To the best of our knowledge, this is the first reported case of C-MYC DM-containing de novo large B-cell lymphoma, which was successfully treated with complete remission, but unfortunately died of t-AML harboring t(3;3)(q21;q26).

KEYWORDS:

C-MYC; Double minute; Large B-cell lymphoma; Therapy-related acute myeloid leukemia; t(3 ;3)(q26.2 ;q21)

PMID:
26300063
DOI:
10.1016/j.prp.2015.07.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center